← All organizations
Highest phase reached
Phase 3
First clinical trial
Jan 1, 1993Last known activity
Feb 7, 2025
Timeline
1970s
- Jun 1, 1978
Japan Clinical Oncology Group— Founded
Drugs by trial phase (36 distinct, 24 trials)
Phase 3 (32 own, 0 via acquisition)
Phase 2 (4 own, 0 via acquisition)
Indications
Studied for
- Breast Neoplasms
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Squamous Cell
- Colorectal Neoplasms
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Fallopian Tube Neoplasms
- Glioblastoma
- Leukemia
- Leukemia-Lymphoma, Adult T-Cell
- Leukemia, T-Cell
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Second Primary
- Ovarian Neoplasms
- Pancoast Syndrome
- Pericardial Effusion
- Peritoneal Neoplasms
- Recurrence
- Small Cell Lung Carcinoma
- Stomach Neoplasms
- Uterine Cervical Neoplasms
Recent trials (31)
- NCT07190443CollaboratorPhase 3Feb 7, 2025
- NCT06535893CollaboratorPhase 2Jun 24, 2024
- NCT06940791CollaboratorPhase 2Oct 6, 2023
- NCT04465968CollaboratorPhase 3Sep 1, 2020
- NCT02761070CollaboratorPhase 3Jul 1, 2016
- NCT00295789Lead sponsorPhase 3Feb 1, 2006
- NCT00295789Sponsor investigatorPhase 3Feb 1, 2006
- NCT00252161Lead sponsorPhase 3Nov 1, 2005
- NCT00252161Sponsor investigatorPhase 3Nov 1, 2005
- NCT00132665Lead sponsorPhase 3Jul 1, 2003
- NCT00190476Lead sponsorPhase 3Apr 1, 2003
- NCT00190515Lead sponsorPhase 3Feb 1, 2003
- NCT00190515Sponsor investigatorPhase 3Feb 1, 2003
- NCT00112086Lead sponsorPhase 2Jan 1, 2003
- NCT00149201Lead sponsorPhase 3Nov 1, 2002
Details
- Founded
- Tokyo, JP Jun 1, 1978
- Last known activity
- Feb 7, 2025